Aleor gets tentative USFDA nod for drug for topical treatment

Efinaconazole Topical Solution, 10% is indicated for the topical treatment of onychomycosis of the toenail

47
FDA

Alembic Pharmaceuticals announced that its joint venture Aleor Dermaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Efinaconazole Topical Solution, 10%. T

he approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Jublia Topical Solution, 10%, of Bausch Health Americas, Inc. (Bausch).

Efinaconazole Topical Solution, 10% is indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.

Prescription Medicine Doctor
Picture: Pixabay

Efinaconazole Topical Solution, 10% has an estimated market size of $233 million for twelve months ending December 2020 according to IQVIA.

Aleor has settled the case with Bausch Health and will launch its generic as per the terms of settlement.

Alembic has a cumulative total of 140 ANDA approvals (123 final approvals and 17 tentative approvals) from USFDA.


Also read:

Zydus Cadila gets final USFDA nod for drug to treat High…

Dr Reddy’s launch generic Sapropterin Dihydrochloride Powder for Oral Solution in…

Camber Pharma Launches Generic Succinylcholine Chloride Inj

Aleor gets USFDA nod for drug for cutaneous candidiasis treatment

Zealand Pharma got USFDA nod for severe Hypoglycemia drug

Glenmark gets USFDA nod for Chlorpromazine HCL tablets


Enter your email address:

Delivered by FeedBurner

Latest updates

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Go to main website, click here

Follow and connect with us on Facebook and Linkedin

For daily free updates on WhatsApp, click here

Subscribe here for daily updates
Loading